Yazarlar : Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM, Witzig TE.

Yayın : Blood.

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21673350

Konu : Lenfoma

Literatür İçeriği :  

Abstract

Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab-CHOP chemoimmunotherapy; new treatments building on the R-CHOP backbone are needed. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase II trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in patients with untreated DLBCL. A secondary aim was to assess the efficacy of interim PET to predict outcome in DLBCL. Standard R-CHOP with the addition of E 360 mg/m(2) IV was administered for 6 cycles. 107 patients were enrolled on the study. The regimen was well tolerated and toxicity was similar to standard R-CHOP. ORR in the 81 eligible patients was 96% (74% CR/CRu,) by CT scan and 88% by PET. By intention to treat analysis, at a median follow-up of 43 months, the EFS and OS at 3 years in all 107 patients were 70% and 80%, respectively. Interim PET was not associated with EFS or OS. Comparison with a cohort of 215 pts who were treated with R-CHOP showed an improved EFS in the ER-CHOP patients. ER-CHOP is well-tolerated and phase II results appear promising as a combination therapy. This study is registered at http://Clinicaltrials.gov as NCT00301821.

Literatür Arşivi